Paper42903486PubMed
Boosting CAR-T cell therapy with CRISPR technology.
Yan L and 5 others. Hlife, 2024.
Cite this record
ConductScience Library. Boosting CAR-T cell therapy with CRISPR technology. Papers, record 42903486. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42903486
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Boosting CAR-T cell therapy with CRISPR technology.
- Journal
- Hlife
- Year
- 2024
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-10-23
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References188
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30804938 | CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. | Front Immunol | 2019 | https://conductscience.org/library/papers/30804938 | PubMed |
| 2 | 34218353 | Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies. | Curr Med Sci | 2021 | https://conductscience.org/library/papers/34218353 | PubMed |
| 3 | 37980345 | Genome-wide CRISPR off-target prediction and optimization using RNA-DNA interaction fingerprints. | Nat Commun | 2023 | https://conductscience.org/library/papers/37980345 | PubMed |
| 4 | 22592077 | The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells. | J Exp Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22592077 | PubMed |
| 5 | 29385370 | Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29385370 | PubMed |
| 6 | 31953246 | Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma. | Cancer Immunol Res | 2020 | https://conductscience.org/library/papers/31953246 | PubMed |
| 7 | 38658804 | Tonic-ing emissions and compatibility to turbocharge CAR-T. | Nat Metab | 2024 | https://conductscience.org/library/papers/38658804 | PubMed |
| 8 | 34035409 | Base-edited CAR T cells for combinational therapy against T cell malignancies. | Leukemia | 2021 | https://conductscience.org/library/papers/34035409 | PubMed |
| 9 | 31391096 | PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/31391096 | PubMed |
| 10 | 26738796 | Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. | Sci Transl Med | 2016 | https://conductscience.org/library/papers/26738796 | PubMed |
| 11 | 37945901 | Transcriptional and epigenetic regulators of human CD8+ T cell function identified through orthogonal CRISPR screens. | Nat Genet | 2023 | https://conductscience.org/library/papers/37945901 | PubMed |
| 12 | 29414259 | CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. | Annu Rev Med | 2018 | https://conductscience.org/library/papers/29414259 | PubMed |
| 13 | 37041195 | Engineered CRISPR-OsCas12f1 and RhCas12f1 with robust activities and expanded target range for genome editing. | Nat Commun | 2023 | https://conductscience.org/library/papers/37041195 | PubMed |
| 14 | 21739672 | T cell exhaustion. | Nat Immunol | 2011 | https://conductscience.org/library/papers/21739672 | PubMed |
| 15 | 24876563 | Current concepts in the diagnosis and management of cytokine release syndrome. | Blood | 2014 | https://conductscience.org/library/papers/24876563 | PubMed |
| 16 | 30941126 | Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing. | Front Immunol | 2019 | https://conductscience.org/library/papers/30941126 | PubMed |
| 17 | 36972454 | Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion. | Proc Natl Acad Sci U S A | 2023 | https://conductscience.org/library/papers/36972454 | PubMed |
| 18 | 33907185 | CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy. | Cell Discov | 2021 | https://conductscience.org/library/papers/33907185 | PubMed |
| 19 | 24553386 | Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. | Sci Transl Med | 2014 | https://conductscience.org/library/papers/24553386 | PubMed |
| 20 | 37192099 | Discovery of Diverse CRISPR-Cas Systems and Expansion of the Genome Engineering Toolbox. | Biochemistry | 2023 | https://conductscience.org/library/papers/37192099 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41015605 | Engineering adoptive cell therapy for solid tumors. | Med Oncol | 2025 | https://conductscience.org/library/papers/41015605 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42903486
GET https://conductscience.org/api/papers/v1/42903486/references?page=2